The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Fidelity Select Biotechnology FBIOX
- NAV / 1-Day Return 17.58 / +0.86 %
- Total Assets 4.9 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.720%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.41%
- Turnover 51%
USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:14 PM GMT+0
Morningstar’s Analysis FBIOX
Will FBIOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 13.46 | 661.8 Mil | Healthcare |
Amgen Inc | 7.11 | 349.6 Mil | Healthcare |
Krystal Biotech Inc | 6.44 | 316.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.22 | 207.6 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.16 | 155.6 Mil | Healthcare |
Gilead Sciences Inc | 2.19 | 107.8 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 2.01 | 98.8 Mil | Healthcare |
Ascendis Pharma A/S ADR | 1.98 | 97.4 Mil | Healthcare |
Apellis Pharmaceuticals Inc | 1.71 | 84.2 Mil | Healthcare |
Arcellx Inc | 1.70 | 83.5 Mil | Healthcare |